Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers1 The...
Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy...
First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when added to standard of care over 24 weeks in antibody positive...
Data released earlier this month showed that across nearly 600 cancer patient groups, Roche was rated as having the best reputation among pharmas in 2023. Now, PatientView has offered an even deeper dive into those findings, breaking out patient sentiments by several cancer types.
A jury found J&J’s Janssen liable for $150 million in damages in New Jersey federal court last week, ruling that the company owed $120 million …
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9 years1. Additional findings from pooled analysis of three Phase 3 studies show treatment with ibrutinib has the potential to achieve comparable overall survival to the general European population2
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM, June 14, 2024 (GLOBE NEWSWIRE) --...
24-month overall survival rate of 67 percent achieved with talquetamab 0.8mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study1 BEERSE, BELGIUM , June 14, 2024 (GLOBE NEWSWIRE) --...
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing1 Separate analyses from the MajesTEC-1 and...
73 percent reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1 ...